Renal Cell Carcinoma
Conference Coverage
Tivozanib has PFS benefit over sorafenib in hard-to-treat RCC
SAN FRANCISCO – In the TIVO-3 trial, tivozanib prolonged progression-free survival by about 2 months, compared with sorafenib, in patients with...
Conference Coverage
First-line avelumab/axitinib for RCC benefits wide range of patients
SAN FRANCISCO – Subgroup analyses of the JAVELIN Renal 101 trial show that first-line avelumab/axitinib yields better PFS and ORRs than sunitinib...
Conference Coverage
Pembrolizumab-axitinib nearly halves risk of death in RCC
SAN FRANCISCO – Pembrolizumab and axitinib combination therapy netted superior progression-free and overall survival relative to sunitinib in...
Latest News
Severe adverse events seen in placebo arm of cancer clinical trials
A significant number of patients treated only with placebo during cancer clinical trials still report serious adverse events.
From the Journals
‘Optimal’ pazopanib levels linked to lower toxicity in RCC patients
Therapeutic drug monitoring may help optimize dosing and limit toxicity, though larger studies are needed to validate this small, retrospective...
From the Journals
Cytoreductive nephrectomy may benefit RCC patients with brain mets
In an analysis of SEER data, 2-year survival was 52% and 14%, respectively, for RCC patients with brain-only metastases who did and did not...
From the Journals
Lipoprotein ratio linked to poor survival in metastatic RCC
In a retrospective study of data on 287 metastatic RCC patients who underwent cytoreductive nephrectomy, the ratio of apolipoproteins B and A1 was...
From the Journals
RCC strongly linked to melanoma, and vice versa
Clinicians need to be vigilant for RCCs in melanoma patients, and for melanomas in RCC patients.
From the Journals
RCC research has opened door to the future, but “much work remains to be done”
Future efforts should aim to link genetic knowledge with prognosis and treatment selection.
From the Journals
hTERT expression predicts RCC survival, tumor aggressiveness
Disease-specific survival was lowest in ccRCC patients with high human telomerase reverse transcriptase protein expression.
From the Journals
Age-related gene expression may affect responses to RCC therapy
Older patients with ccRCC may respond better than younger patients to phosphoinositide 3-kinase (PI3K) or checkpoint inhibition because of age-...